Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, double-blind, placebo-controlled, multiple dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of YTX-7739, a novel oral inhibitor of Stearoyl-CoA-desaturases, in healthy volunteers and patients with Parkinson's disease

Next Previous
Trial Profile

Randomized, double-blind, placebo-controlled, multiple dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of YTX-7739, a novel oral inhibitor of Stearoyl-CoA-desaturases, in healthy volunteers and patients with Parkinson's disease

Status: Suspended
Phase of Trial: Phase I

Latest Information Update: 24 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs YTX 7739 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms CHDR1916/7739-01-002
  • Sponsors Yumanity Therapeutics

Most Recent Events

  • 19 Jan 2022 According to a Yumanity Therapeutics media release, in response to IND application submitted in December 2021, the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on multidose clinical trials of YTX-7739. The FDA has not halted single dose clinical trials. The partial clinical hold suspends initiation of multiple dose clinical trials in the U.S. until the FDA's questions have been addressed.
  • 19 Jan 2022 Status changed from recruiting to suspended, according to Yumanity Therapeutics Media Release.
  • 10 Nov 2021 According to Yumanity Therapeutics Media Release, the full data set from this study will be presented at an upcoming medical conference; Management will host a conference call to discuss the results of the Phase 1b clinical trial at 8:30 a.m. EST, Wednesday, November 10.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top